chufangao/CTO huggingface dataset:
Clinical trial NCT04900766: A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma
Official title: A Multicenter, Open-label, Phase Ib Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma Who Has Failed At Least One Prior Line of Therapy
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The sponsor has adjusted its R\&D strategy.
Enrollment: 31.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-08-11
Primary completion date: 2023-02-03
Completion date: 2023-02-03
Plan to share individual participant data: NO
Clinical trial NCT04154735: Autologous Transplant Targeted Against Crohn's
Official title: Autologous Hematopoietic Stem Cell Transplant for Crohn's Disease
Acronym: ATTAC
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Discontinued by Investigator
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-30
Primary completion date: 2023-03-31
Completion date: 2024-03-31
Plan to share individual participant data: NO
Clinical trial NCT03397186: Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
Official title: An Analysis of the Changes in the Sarcoma Tumor Immune Microenvironment Following Trabectedin
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Administrative
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-06-19
Primary completion date: 2021-01-01
Completion date: 2021-05-01
Plan to share individual participant data: NO
Clinical trial NCT04002622: Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
Official title: A Phase II, Multicenter, Open, Single-arm Study of TQB2450 Injection (PD-L1 Antibody) in Subjects With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The population of target indication is small and screening is difficult.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-08-06
Primary completion date: 2021-01-21
Completion date: 2021-01-21
Clinical trial NCT04512079: FREEDOM COVID-19 Anticoagulation Strategy
Official title: FREEDOM COVID Anticoagulation Strategy Randomized Trial
Acronym: FREEDOM COVID
Sponsor: Icahn School of Medicine at Mount Sinai (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 3460.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-09-08
Primary completion date: 2022-12-30
Completion date: 2022-12-30
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
IPD time frame: Beginning 9 months and ending 36 months following article publication.
IPD access criteria: Investigators whose proposed use of the data has been approved by an independent review committee (learned intermediary) identified for this purpose. The type of analysis that will be conducted is for individual participant data meta-analysis. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata.
Clinical trial NCT05222269: [68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients
Official title: A Prospective, International, Multi-centre, Open-label, Single-arm Phase II Study Investigating the Predictive Value of [68Ga]Ga PentixaFor PET Imaging in Primary and Isolated Secondary CNS Lymphoma Patients
Sponsor: Pentixapharm AG (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was early terminated due to low patient recruitment in already activated sites and difficult approval process in some of the anticipated countries. Thus, recruitment of the planned patient numbers in a reasonable time cannot be expected.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-10-05
Primary completion date: 2023-01-25
Completion date: 2023-01-25
Clinical trial NCT03697239: High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Official title: Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer
Sponsor: University of California, San Diego (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: FDA indicated the same study could not be conducted under multiple INDs
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-06-30
Primary completion date: 2021-12-31
Completion date: 2022-12-31
Clinical trial NCT02785120: A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes
Official title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Study to Evaluate the Efficacy and Safety of TF0023 Spray Versus Placebo in Functional Improvement of Patients With Ischemic Strokes
Acronym: TF0023
Sponsor: Techfields Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: Suspended due to enrollment challenges and business operations.
Enrollment: 225.0 (ESTIMATED)
Number of arms: 3.0
Start date: 2017-03-01
Primary completion date: 2024-10-31
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT02515669: Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD
Official title: A Multi-Site, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7239361 (BMS-986089) in Ambulatory Boys With Duchenne Muscular Dystrophy
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: A pre-planned futility analysis indicated lack of efficacy in study NCT03039686 and led to discontinuation of both ongoing studies in DMD.
Enrollment: 43.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-12-02
Primary completion date: 2018-02-08
Completion date: 2020-04-15
Baseline population: Doses tested in this study were based upon achieving and maintaining moderate (\> 50% suppression), high (\> 85%), and near complete (\> 95%) suppression of serum free myostatin levels for Panels 1, 2, and 3 and Expansion Panel, respectively. Panel 3 was expanded after at least 2 weeks of dosing had been complete by at least 6 participants.
Clinical trial NCT04987294: Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease
Official title: A Randomized, Double-Blind, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects With Gout and Mild to Moderate Chronic Kidney Disease
Sponsor: Allena Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Company Financing
Enrollment: 19.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-09-02
Primary completion date: 2022-09-02
Completion date: 2022-09-02
Plan to share individual participant data: NO
Clinical trial NCT03666143: A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Official title: A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 216.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-11-01
Primary completion date: 2023-01-05
Completion date: 2023-01-05
Plan to share individual participant data: YES
Clinical trial NCT04159493: A Randomized Controlled Phase 2 Study to Determine Lowest Efficacious Dose of Ovestin in Vulvar and Vaginal Atrophy
Official title: A Randomized, Double-blind, Placebo-Controlled, Dose De-escalation Phase 2 Study of Various Doses of Ovestin in the Treatment of Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women
Acronym: DOVE
Sponsor: Aspen Global Incorporated (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Project terminated IND withdrawn
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-05
Primary completion date: 2023-02-28
Completion date: 2023-05-15
Plan to share individual participant data: NO
Clinical trial NCT02576795: Gene Therapy Study in Severe Haemophilia A Patients (270-201)
Official title: A Phase 1/2, Dose-Escalation, Safety, Tolerability and Efficacy Study of Valoctocogene Roxaparvovec, an Adenovirus-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Patients With Severe Haemophilia A
Sponsor: BioMarin Pharmaceutical (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-09-28
Primary completion date: 2024-02-14
Completion date: 2024-02-14
Clinical trial NCT04272034: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Official title: A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Select Advanced Solid Tumors
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
Enrollment: 105.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-03-26
Primary completion date: 2024-08-16
Completion date: 2024-08-16
Plan to share individual participant data: NO
IPD sharing description: Access to patient level data is not available for this study
Clinical trial NCT02053246: Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure
Official title: Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure
Sponsor: University of Florida (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study funding ended before recruitment completed.
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-01-31
Primary completion date: 2021-03-31
Completion date: 2021-03-31
Limitations and caveats: Trial was stopped prior to completion because funding ended.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03820258: Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection
Official title: A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed Dose Combination in Adolescents and Children With Chronic HCV Infection
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: SOF/VEL/VOX will not be evaluated in younger age groups.
Enrollment: 21.0 (ACTUAL)
Number of arms: 6.0
Start date: 2019-01-28
Primary completion date: 2019-12-04
Completion date: 2020-02-19
Baseline population: The Safety Analysis Set included participants who received at least 1 dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy
IPD time frame: 18 months after study completion
IPD access criteria: A secured external environment with username, password, and RSA code.
Clinical trial NCT03405714: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy
Official title: A Multicenter, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month < 16 Years of Age With Epilepsy
Sponsor: UCB Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-06-01
Primary completion date: 2020-11-04
Completion date: 2020-11-04
Baseline population: Baseline Characteristics refer to SS-iv, which included study participants who received at least 1 dose of iv BRV.
Plan to share individual participant data: NO
Clinical trial NCT03230097: This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
Official title: A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered BI 409306 During a 52-week Treatment Period as an Early Intervention in Patients With Attenuated Psychosis Syndrome.
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: disruption due to COVID-19
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-29
Primary completion date: 2021-03-17
Completion date: 2021-04-07
Baseline population: The treated set (TS) includes all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.
Limitations and caveats: The sponsor decided to prematurely stop enrollment. This decision was based on the unfortunate inability to meet expected enrolment goals, a situation made far worse by the impact of the COVID-19 pandemic.
Clinical trial NCT05047523: Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
Official title: A Multicenter, Randomized, Controlled, Open-label, Rater-blinded Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
Sponsor: Alexion Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor decision to terminate the program
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-13
Primary completion date: 2023-06-26
Completion date: 2023-06-26
Baseline population: Full Analysis Set (FAS) included all participants who received at least 1 dose of ALXN1840 or SoC treatment.
Limitations and caveats: Due to early termination of the study, data for the efficacy endpoints were not collected.
Clinical trial NCT04746963: Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration
Official title: Phase 1/2a Study of the Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Acronym: SHASTA
Sponsor: AsclepiX Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Adverse Events
Enrollment: 3.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-02-01
Primary completion date: 2022-10-01
Completion date: 2022-10-01
Clinical trial NCT02250651: Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension
Official title: The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension
Sponsor: Allergan (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 528.0 (ACTUAL)
Number of arms: 3.0
Start date: 2014-12-15
Primary completion date: 2018-10-25
Completion date: 2020-07-22
Baseline population: Intent-to-treat (ITT) Population included all randomized participants.
Clinical trial NCT04243681: Combination of Autologous MSC and HSC Infusion in Patients With Decompensated Cirrhosis
Official title: Combination of Autologous Mesenchymal and Hematopoietic Stem Cell Infusion in Patients With Decompensated Cirrhosis: A Pilot Study
Sponsor: Asian Institute of Gastroenterology, India (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-01
Primary completion date: 2020-08-01
Completion date: 2020-09-01
Clinical trial NCT03658616: Assessment of Efficacy and Safety of Topical Administration of 1% Glycopyrronium Bromide (GPB) in Patients With Primary Axillary Hyperhidrosis and the Assessment of Long-term Efficacy and Safety of Topical Administration of 1% GPB Cream in Patients With Primary Axillary Hyperhidrosis.
Official title: Combined Randomized, Double-blind, Dose-confirming Phase 3a Study in Parallel Design to Assess the Efficacy and Safety of Topical 4-week Treatment With 1% GPB Cream vs Placebo and Open-label Phase 3b Study to Assess Long-term Efficacy and Safety in Patients With Primary Axillary Hyperhidrosis Treated With 1% GPB Cream
Sponsor: Dr. August Wolff GmbH & Co. KG Arzneimittel (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 518.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-18
Primary completion date: 2021-11-02
Completion date: 2022-02-02
Clinical trial NCT05456269: A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS
Official title: An Open-label Two Strata Study of Bisantrene in Combination With Cytarabine Arabinoside or Bisantrene in Combination With Oral Decitabine/Cedazuridine for the Treatment of Acute Myeloid Leukemia Patients With Extramedullary Disease
Acronym: BISECT
Sponsor: Race Oncology Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: commercial reason
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-07-29
Primary completion date: 2023-08-31
Completion date: 2023-08-31
Plan to share individual participant data: NO
Clinical trial NCT03600818: Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica
Official title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Protracted recruitment timeline exacerbated by COVID-19 pandemic
Enrollment: 118.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-09
Primary completion date: 2021-05-19
Completion date: 2021-05-19
Baseline population: Analysis was performed on randomized population.
Limitations and caveats: Protracted recruitment timeline exacerbated by COVID-19 pandemic led to pre-mature termination of study, resulting in a change in the total expected number of participants and change in the statistical significance level.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT04563702: Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
Official title: A Phase 1 Open-Label, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Vaccine (VXA-CoV2-1) Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant Administered Orally to Healthy Adult Volunteers VXA-CoV2-1.1-S Boost Substudy: Boost at 1 Year Post Initial Vaccination With an Adenoviral-Vector Based Vaccine VXA-CoV2-1.1-S Expressing a SARS-CoV-2 S Protein in a Subset of Subjects
Sponsor: Vaxart (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 35.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-21
Primary completion date: 2021-10-10
Completion date: 2021-10-10
Plan to share individual participant data: UNDECIDED
IPD sharing description: A plan on how to share individual subject's outcomes will be defined within the next few months.
Clinical trial NCT02419105: Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors
Official title: Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors. Double Blind, 2x2 Factorial, Randomized Placebo--Controlled Clinical Trial
Acronym: T&D
Sponsor: University of Zurich (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Delayed recruitment mainly due to a screening to inclusion rate much lower than expected. Due to the delayed recruitment IMP reached the end of its shelf life.
Enrollment: 91.0 (ACTUAL)
Number of arms: 4.0
Start date: 2015-09-30
Primary completion date: 2020-05-31
Completion date: 2020-06-30
Clinical trial NCT04782661: A Study of JNJ-70075200 in Healthy Participants
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of JNJ-70075200 in Healthy Participants
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Program terminated prior to enrolling subjects
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-03-01
Primary completion date: 2022-05-09
Completion date: 2022-09-23
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT04453371: Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19)
Official title: Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (Microvascular COVID-19 Lung Vessels Obstructive Thromboinflammatory Syndrome (MicroCLOTS): A Multicentral Randomized Trial (AtTAC-trial)
Acronym: AtTAC
Sponsor: Negovsky Reanimatology Research Institute (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Our local committee has denied the approval request
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-15
Primary completion date: 2021-01-15
Completion date: 2021-02-15
Clinical trial NCT04525898: Intraoperative Methadone for Postoperative Pain Control After Thoracic Surgery
Official title: Intraoperative Methadone for Postoperative Pain Control After Thoracic Surgery
Sponsor: NorthShore University HealthSystem (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Investigator left institution
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-09
Primary completion date: 2021-02-01
Completion date: 2021-02-01
Plan to share individual participant data: NO
IPD sharing description: Data not to be shared